Testosterone
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
- Testosterone
- Testosterone: From Hypogonadotropic Hypogonadism and Pituitary Hormone Deficiency to Polysomy of X Chromosome
Testosterone: From Hypogonadotropic Hypogonadism and Pituitary Hormone Deficiency to Polysomy of X Chromosome
One-Sentence Summary
Testosterone is an androgen replacement hormone, originally used for hypogonadism (including hypogonadotropic hypogonadism and Kallmann syndrome) and pituitary hormone deficiencies. The TxGNN model predicts it may be effective for polysomy of X chromosome, but this top-ranked prediction has 0 clinical trials and 0 publications behind it. The data compiled for this report show stronger support for other predicted indications, notably primary ovarian failure (2 trials, 20 publications) and testicular regression syndrome (20 publications, no trials). These are discussed below.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Hypogonadotropic hypogonadism, hypopituitarism, Kallmann syndrome and related pituitary hormone deficiencies (the Singapore licence records contain no approved indication text) |
| Predicted New Indication | Polysomy of X chromosome (top-ranked prediction) |
| TxGNN Prediction Score | 94.88% |
| Evidence Level | L5 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 3 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available. Testosterone is the main male sex hormone, and it is established practice to use it to replace missing androgen in hypogonadism. Its efficacy in the original conditions rests on this replacement role.
The link to X polysomy is indirect. Testosterone replacement is plausible in sex chromosome aneuploidies that come with hypogonadism (for example 47,XXY). The entity named here, X polysomy, is not directly supported by any data compiled for this report. The link is inferred from the knowledge graph and has not been demonstrated.
Other top-ranked predictions vary widely in plausibility:
- Testicular regression syndrome, penile/testicular agenesis and Leydig cell hypoplasia: Androgen is absent or poorly produced, so replacement is biologically reasonable.
- Primary ovarian failure: Ovarian androgen output falls along with estrogen, so adding testosterone to estradiol has been proposed. This is the only prediction with registered trials.
- Tetragametic chimerism, freemartinism, urethral obstruction sequence and arthrogryposis with epileptic seizures: No convincing therapeutic rationale. The freemartinism literature is entirely animal research, and androgen insensitivity would make testosterone ineffective.
Clinical Trial Evidence
No clinical trials are registered for the top-ranked prediction (polysomy of X chromosome). The only trials in the data are for the rank-10 prediction, primary ovarian failure:
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT06343870 | Phase 3 | Recruiting | 140 | Estradiol plus testosterone subdermal implants in women with natural menopause, premature ovarian failure or surgical menopause. Evaluates pharmacokinetic, hormonal and clinical effects. No results yet. |
| NCT01662466 | Phase 1/2 | Unknown | 180 | Randomized, double-blind, placebo-controlled trial of transdermal testosterone in women with diminished ovarian reserve undergoing IVF. Outcomes include oocyte and embryo quality and pregnancy rates. |
Literature Evidence
The top-ranked prediction has no literature. The most relevant publications are listed below for the two predictions with the most literature. These are testicular regression syndrome and primary ovarian failure, and neither is the rank-1 indication.
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 39647506 | 2024 | Guideline | Climacteric | Evidence-based guideline on diagnosis and management of premature ovarian insufficiency. The data do not show its conclusions on testosterone. |
| 39660328 | 2024 | Guideline | Human Reproduction Open | Same POI guideline, published in a second journal. |
| 39652037 | 2025 | Guideline | Fertility and Sterility | Same POI guideline, published in a third journal. |
| 41448220 | 2025 | Systematic review/meta-analysis | Lancet Healthy Longevity | Menopause hormone therapy and risk of mild cognitive impairment or dementia. |
| 12099669 | 2002 | Review | Best Pract Res Clin Obstet Gynaecol | Role of androgen therapy in women, including androgen deficiency. |
| 31327696 | 2019 | Review | Best Pract Res Clin Endocrinol Metab | Primary gonadal failure in males and females, including disorders of sex development. |
| 31013155 | 2019 | Cohort/Survey | Endocr Pract | Retrospective review of 57 patients with testicular regression syndrome. Diagnosis and management varied widely between patients. |
| 15799128 | 2004 | Review | Aging Male | Testosterone therapy in male hypogonadism, including anorchia and Klinefelter syndrome. |
| 1818010 | 1991 | Review | Hormone Research | Indications for androgen treatment in delayed puberty and hypogonadism in boys. Congenital anorchia is the prototype condition needing replacement. |
| 35035874 | 2022 | Review | Ther Adv Endocrinol Metab | Recent advances in treating boys and adolescents with hypogonadism. |
Several retrieved items are off-topic, for example testicular tumour radiotherapy and tissue-engineered prostheses.
Singapore Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN13161P | Androgel 25mg | Gel | Not stated in the records |
| SIN16857P | ANDROGEL GEL 16.2MG/G | Gel | Not stated in the records |
| SIN13162P | Androgel 50mg | Gel | Not stated in the records |
All three registrations are valid single-ingredient topical gels.
Safety Considerations
- Contraindications suggested by the knowledge graph (not label text): hypertension, epilepsy, kidney disease, liver disease, gallbladder disease, congestive heart failure, hypothyroidism, systemic lupus erythematosus, asthma, diabetes mellitus and diabetic ketoacidosis, benign prostatic hyperplasia, hypercalcaemia, hypertriglyceridaemia, gynaecomastia, female breast carcinoma, thrombophlebitis and uterine leiomyoma.
- Drug Interactions: 100 interactions were found. All 20 listed in the data are rated Moderate. They fall mainly into three groups:
- corticosteroids (hydrocortisone, betamethasone, budesonide, dexamethasone)
- antidiabetic agents (sulfonylureas such as glimepiride, glipizide and glyburide, and multiple insulins)
- others, including aprepitant and topical calcitriol
Please refer to the package insert for warnings and contraindications from the label.
Conclusion and Next Steps
Decision: Hold
Rationale: The top-ranked prediction, polysomy of X chromosome, rests on a model score alone (L5), with no trials or literature, and the link to testosterone is inferred rather than demonstrated. The best-supported alternative, primary ovarian failure, has a recruiting Phase 3 trial and a Phase 1/2 randomized trial. Neither has results, so the evidence level is not yet L1 or L2.
To proceed, the following is needed:
- Package insert warnings and contraindications from the Singapore regulator (HSA), which are currently missing and block safety screening
- Detailed mechanism of action data
- Results from NCT06343870 and NCT01662466 before considering primary ovarian failure further
- Clinical evidence specific to X polysomy, or a decision to prioritize testicular regression syndrome, where testosterone replacement is already standard reasoning
- A review of the topical gel formulations against the dosing and route needs of any chosen indication
- Careful review of the knowledge-graph contraindications (especially cardiovascular, hepatic, renal and breast or prostate conditions) for the target population
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.